# US 2001/0026812 A1 · Method for determining the three-dimensional structure of a protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0026812 A1
- Document ID: US20010026812A1
- Status: Published application
- Kind: A1
- Application number: 09/774,168
- Filed: 2001-01-26
- Published: 2001-10-04
- Earliest claimed: 1994-12-02
- Assignees: Government of the United States of America, National Aeronautics & Space Administration
- Inventors: Dennis R. Morrison; Benjamin Mosier
- Web page: https://patentgrep.com/patent/US20010026812A1

## CPC

- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 9/5089: {Processes}
- A61K 41/0028: {Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds}
- B01J 13/06: by phase separation
- C30B 7/00: Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions (from molten solvents C30B9/00; by normal or gradient freezing C30B11/00; under a protective fluid C30B27/00)
- B01F 33/30: Micromixers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C30B: SINGLE-CRYSTAL GROWTH (by using ultra-high pressure, e.g. for the formation of diamonds, B01J3/06); UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL (zone-refining of metals or alloys C22B); PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE (casting of metals, casting of other substances by the same processes or devices B22D; working of plastics B29; modifying the physical structure of metals or alloys C21D, C22F); SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE (for producing semiconductor devices or parts thereof H10); APPARATUS THEREFOR
- B01F: MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING (mixing paints B44D3/06)

## Abstract

Microcapsules prepared by encapsulating an aqueous solution of a protein, drug or other bioactive substance inside a semi-permeable membrane by are disclosed. The microcapsules are formed by interfacial coacervation under conditions where the shear forces are limited to 0-100 dynes/cm2 at the interface. By placing the microcapsules in a high osmotic dewatering solution, the protein solution is gradually made saturated and then supersaturated, and the controlled nucleation and crystallization of the protein is achieved. The crystal-filled microcapsules prepared by this method can be conveniently harvested and stored while keeping the encapsulated crystals in essentially pristine condition due to the rugged, protective membrane. Because the membrane components themselves are x-ray transparent, large crystal-containing microcapsules can be individually selected, mounted in x-ray capillary tubes and subjected to high energy x-ray diffraction studies to determine the 3-D structure of the protein molecules. Certain embodiments of the microcapsules of the invention have composite polymeric outer membranes which are somewhat elastic, water insoluble, permeable only to water, salts, and low molecular weight molecules and are structurally stable in fluid shear forces typically encountered in the human vascular system.

## Claims

### Claim 1

A method of making a microcapsule comprising:
preparing a first phase comprising a first solvent, a co-solvent and a first polymer dissolved therein;
preparing a second phase of different density than said first phase, said second phase comprising a second solvent, a surfactant, a salt, and a bioactive substance which is capable of forming a highly ordered structure dissolved therein;
selecting said first polymer and surfactant such that the hydrophobic/lipophilic balance value (HLB) of the surfactant is greater than the HLB of said first polymer, and said first and second phases are capable of forming an interface therebetween;
creating an interface between said first and second phases and limiting fluid shear forces to about 0-100 dynes/cm2 at said interface.

### Claim 2 (depends on 1)

The method of claim 1 wherein said second phase further comprises a second polymer dissolved therein and said first polymer, second polymer and surfactant are selected such that the respective hydrophobic/lipophilic balance values (HLB) are surfactant>second polymer>first polymer.

### Claim 3 (depends on 1)

The method of claim 1 wherein said shear forces are limited to about 0-12 dynes/cm2.

### Claim 4 (depends on 1)

The method of claim 1 wherein said bioactive substance is a protein.

### Claim 5 (depends on 3)

The method of claim 3 wherein said protein is dissolved in said second phase and the concentration of said protein is at or near saturation.

### Claim 6 (depends on 4)

The method of claim 4 wherein said second phase also comprises said protein in crystalline form.

### Claim 7 (depends on 1)

The method of claim 1 wherein said second phase also comprises a protein stabilizing agent.

### Claim 8 (depends on 1)

The method of claim 1 wherein said first solvent is chosen from the group consisting of water, methanol, ethanol, isopropanol, n-hexanol, n-heptanol and hydrocarbons having a low or medium HLB 5-10.

### Claim 9 (depends on 1)

The method of claim 1 wherein said co-solvent is chosen from the group consisting of: a 3-carbon to 8-carbon (C3-C8) normal alcohol, tetrahydrofuran, dioxane, acetonitrile, dimethylformamide, dimethylacetamide, dimethylsulfoxide and similar solvents.

### Claim 10 (depends on 1)

The method of claim 1 wherein said first polymer is chosen from the group consisting of: glycerol monostearate, glycerol monooleate, glycerol monolaurate, glycerol dioleate, glycerol distearate, other hydrophobic mono- or polyglycerides or waxy polymers of low molecular weight, and combinations of any of the foregoing polymers.

### Claim 11 (depends on 1)

The method of claim 1 wherein said first solvent comprises water and said first polymer is a polyethylene glycol having a molecular weight greater than about 400 kDa, cyclodextrin, polyvinylpyrrolidine or polyvinyl alcohol.

### Claim 12 (depends on 1)

The method of claim 1 wherein an alternative membrane forming material comprising a sterol or a phospholipid is substituted for said first polymer, said sterol or phospholipid being chosen from the group consisting of cholesterol, stigmasterol, phytosterol, campesterol, and phosphatydyl choline.

### Claim 13 (depends on 1)

The method of claim 1 wherein said second solvent is water.

### Claim 14 (depends on 1)

The method of claim 1 wherein said surfactant has a hydrophilic/lipophilic balance value (HLB) of about 10-40 and the HLB of said first polymer is less than the HLB of said surfactant by 2 or more HLB units.

### Claim 15 (depends on 1)

The method of claim 1 wherein said surfactant is chosen from the group consisting of sorbitan monooleate plus ethylene oxide, dextran, polyethylene glycol (PEG), C12-C20 fatty acids, and quaternary NH4 salts.

### Claim 16 (depends on 2)

The method of claim 2 wherein said second polymer is capable of adhering to said first polymer and is chosen from the group consisting of PEG 400-20000, dextran 4000-100,000, a polysaccharide of mol. wt. ranging from about 4,000-100,000, polyvinylpyrrolidone (PVP), a polyvinyl alcohol and other similar polymeric materials.

### Claim 17 (depends on 1)

The method of claim 1 wherein said salt is chosen from the group consisting of NaCl, KCl, CaCl2, quaternary NH4 salts, cetyl trimethylammonium bromide, 2-amino-2-methyl aminomethyl propanol, and similar salts.

### Claim 18 (depends on 1)

The method of claim 1 further comprising curing the membrane of said microcapsule.

### Claim 19 (depends on 18)

The method of claim 18 wherein said membrane is permeable to water and low molecular weight molecules and less permeable to said bioactive substance.

### Claim 20 (depends on 1)

The method of claim 1 further comprising dewatering said microcapsule.

### Claim 21 (depends on 18)

The method of claim 18 further comprising isolating a microcapsule having a predetermined size.

### Claim 22 (depends on 18)

The method of claim 18 further comprising exposing said microcapsule to a closed local environment capable of regulating the rate and extent of microcapsule dewatering whereby controlled crystallization of said protein occurs within said microcapsule.

### Claim 23 (depends on 22)

The method of claim 22 wherein said microcapsule dewatering comprises exposing said microcapsules to a dewatering solution containing a salt or a polymer which is excluded by said semi-permeable membrane.

### Claim 24 (depends on 23)

The method of claim 23 wherein said exposing to a closed local environment further comprises controlling the protein concentration and the concentration of charged precipitant molecules at or near the surface of a growing protein crystal whereby the internal order and extent of crystallization of said protein crystal is optimized.

### Claim 25 (depends on 18)

The method of claim 18 further comprising diffusing a low molecular weight salt into said interior cavity whereby single crystal nucleation and crystal growth is induced.

### Claim 26 (depends on 18)

The method of claim 18 further comprising applying an additional coating of polymer to said microcapsule.

### Claim 27 (depends on 18)

The method of claim 18 further comprising applying an additional coating of polymer to said microcapsule.

### Claim 28

A method of making a microcapsule comprising:
preparing a first phase containing
a first solvent chosen from the group consisting of: water, methanol, ethanol, isopropanol, n-hexanol, or n-heptanol, or another hydrocarbon having a low or medium HLB 5-10,
a co-solvent chosen from the group consisting of: a 3-carbon to 8-carbon (C3-C8) normal alcohol, tetrahydrofuran, dioxane, acetonitrile, dimethylformamide, dimethylacetamide, dimethylsulfoxide and similar solvents, and having a first polymer dissolved therein,
said first polymer chosen from the group consisting of glycerol monostearate, glycerol monooleate, glycerol monolaurate, glycerol dioleate, glycerol distearate, other hydrophobic mono- or polyglycerides or waxy polymers of low molecular weight, and combinations of any of the foregoing polymers;
preparing a second phase of different density than said first phase, said second phase comprising
a second solvent comprising water,
a surfactant chosen from the group consisting of sorbitan monooleate plus ethylene oxide, dextran, polyethylene glycol (PEG), C12-C20 fatty acids, and quaternary NH4 salts,
a second polymer capable of adhering to said first polymer and chosen from the group consisting of PEG 400-20000, dextran 4000-100,000, a polysaccharide of mol. wt. ranging from about 4,000-100,000, polyvinylpyrrolidone (PVP), a polyvinyl alcohol and other similar polymeric materials,
a protein and optionally a crystal of said protein, and
a salt chosen from the group consisting of NaCl, KCl, CaCl2, quaternary NH4 salts, cetyl trimethylammonium bromide, 2-amino-2-methyl aminomethyl propanol, and similar salts;
choosing said first polymer, second polymer and surfactant such that the hydrophobic/lipophilic balance values (HLB) are: surfactant HLB>second polymer HLB>first polymer HLB;
creating an interface between said first and second phases; and
limiting fluid shear stress at said interface to 0-100 dynes/cm2;
permitting a microcapsule having an outer membrane to form by interfacial coacervation;
curing said outer membrane of said microcapsule;
optionally dewatering said microcapsule; and
optionally applying an additional polymer coating on said outer membrane.

### Claim 29

An improved method of determining the three-dimensional structure of a predetermined protein molecule by x-ray crystallography including mounting a crystal in an x-ray capillary tube and subjecting said crystal to a high energy x-ray crystallographic procedure to obtain a characteristic x-ray diffraction pattern of said protein crystal, wherein the improvement comprises:
forming a microcapsule containing a saturated or near saturated aqueous solution of said protein surrounded by a semi-permeable polymeric membrane;
exposing said microcapsule to a dewatering solution having a higher osmotic pressure than said encapsulated protein solution whereby water is osmotically removed from said encapsulated protein solution;
controlling the concentration of a dewatering agent in said dewatering solution such that gradual, ordered crystallization of said protein occurs within said microcapsule;
growing said crystal to at least about 50-300 microns;
harvesting the resulting crystal-containing microcapsule;
selecting a microcapsule containing a crystal of sufficient size and crystalline quality for obtaining an acceptable x-ray diffraction pattern.

### Claim 30

An improved method of determining the three-dimensional structure of a predetermined protein molecule by x-ray crystallography including isolating a crystal specimen in a fiber loop having a handle portion, freezing said crystal specimen, mounting said crystal specimen and fiber loop on a goniometer head such that said crystal is positioned in a continuous cold N2 stream loop and kept frozen, and rotating said goniometer in an x-ray beam, wherein the improvement comprises substituting for said crystal specimen a microencapsulated crystal comprising a protective outer membrane surrounding an interior cavity, said interior cavity containing a saturated or nearly saturated solution of a crystal-forming substance and containing a crystal of said substance substantially filling said interior cavity, said membrane being substantially transparent to the x-ray beam.

### Claim 31 (depends on 30)

The method of claim 30 wherein said membrane comprises an electrostatic charge such that said microencapsulated crystal is electrostatically attracted to said loop, said electrostatic attraction being sufficient to support said microencapsulated crystal inside said loop.

### Claim 32 (depends on 30)

The method of claim 30 wherein a drop of liquid is adhered to the outer membrane of said microencapsulated crystal.

### Claim 33 (depends on 30)

The method of claim 30 wherein the outer membrane of said microcapsule is negatively charged and said loop comprises a fiber having a positive electrostatic charge.

### Claim 34 (depends on 30)

The method of claim 30 wherein said fiber is nylon, cellulose, polyethylene terphthlate or other suitable polymer having a surface charge opposite that of said microcapsule.

### Claim 35 (depends on 30)

The method of claim 30 wherein said substance is a protein and said highly ordered structure is a protein crystal.

### Claim 36 (depends on 18)

A microencapsulated protein crystal comprising the product of the method of claim 18.

### Claim 37

A microcapsule comprising an outer membrane surrounding an interior cavity, said interior cavity containing a saturated or nearly saturated solution of a bioactive substance, said microcapsule being capable of withstanding shear forces at least as great as the turbulent blood flow within a human artery.

### Claim 38 (depends on 37)

The microcapsule of claim 37 wherein said membrane comprises at least one membrane forming material chosen from the group consisting of polymers of glycerol monostearate, glycerol monooleate, glycerol monolaurate, glycerol dioleate, glycerol distearate, other hydrophobic mono- or polyglycerides; waxy polymers of low molecular weight, polyethylene glycol (PEG) 1000-8000, dextran 4000-20,000, polysaccharides of mol. wt. ranging from about 10,000-100,000, polyvinylpyrrolidone (PVP), and polyvinyl alcohols; and sterols, phospholipids and lecithins.

### Claim 39

The microcapsule of 37 wherein said membrane comprises a first polymer and a second polymer capable of adhering to said first polymer.

### Claim 40 (depends on 39)

The microcapsule of claim 39 wherein the hydrophilic/lipophilic balance (HLB) of said second polymer is greater than the HLB of said first polymer.

### Claim 41 (depends on 37)

The microcapsule of claim 37 wherein said interior cavity also contains said bioactive substance in the form of a highly ordered structure.

### Claim 42 (depends on 41)

The microcapsule of claim 41 wherein said highly ordered structure is a crystal.

### Claim 43 (depends on 42)

The microcapsule of claim 42 wherein said crystal substantially fills said interior cavity.

### Claim 44 (depends on 43)

The microcapsule of claim 43 wherein said membrane substantially conforms to the shape of said crystal.

### Claim 45 (depends on 44)

The microcapsule of claim 44 wherein said membrane is resistant to piercing by said crystal.

### Claim 46 (depends on 37)

The microcapsule of claim 37 wherein said membrane is permeable to water and low molecular weight salts but impermeable to said bioactive agent.

### Claim 47 (depends on 37)

The microcapsule of claim 37 wherein said membrane is less than or equal to 1 micron in thickness.

### Claim 48 (depends on 37)

The microcapsule of claim 37 wherein said membrane is about 3-5 microns thick.

### Claim 49 (depends on 37)

The microcapsule of claim 37 wherein said bioactive agent is a biomolecule chosen from the group consisting of proteins, polypeptides and oligonucleotides.

### Claim 50 (depends on 42)

The microcapsule of claim 42 wherein said highly ordered structure is about 50-2000 microns in size.

### Claim 51 (depends on 37)

The microcapsule of claim 37 wherein said interior cavity further comprises a hydrophobic phase surrounded by and partially immiscible with said saturated or near-saturated solution of bioactive agent.

### Claim 52 (depends on 37)

A composition comprising a multiplicity of the microcapsule of claim 37 suspended in an aqueous solution having higher osmotic pressure than that of said bioactive agent solution.

### Claim 53 (depends on 52)

The composition of claim 52 wherein said higher osmotic aqueous solution comprises a dewatering agent capable of causing water to be transported through said membrane and out of said interior cavity.

### Claim 54 (depends on 53)

The composition of claim 53 wherein said dewatering agent is a salt or a high molecular weight polymer which is excluded by said membrane.

### Claim 55 (depends on 54)

The microcapsule of claim 54 wherein said polymer is transparent to x-ray radiation and/or does not interfere with the x-ray diffraction pattern of said highly ordered structure.

### Claim 56

An x-ray crystallography reagent for use in elucidating the three-dimensional structure of a predetermined bioactive agent which is capable of forming a highly ordered structure, said reagent comprising a dewatered microcapsule having a polymeric membrane surrounding an interior cavity, said interior cavity containing a saturated or nearly saturated solution of said bioactive agent and containing said bioactive agent in the form of a highly ordered structure substantially filling the interior cavity of said microcapsule.

### Claim 57 (depends on 56)

The reagent of claim 56 wherein said highly ordered structure is a protein crystal.

### Claim 58 (depends on 56)

The reagent of claim 56 wherein said polymeric membrane is electrostatically charged.

### Claim 59 (depends on 57)

The reagent of claim 57 wherein said microcapsule is adapted for being supported electrostatically by a fiber loop having a surface charge different and opposite from said microcapsule.

### Claim 60 (depends on 37)

A pharmaceutical composition comprising a pharmacologically effective multiplicity of the microcapsule of claim 37, together with a pharmacologically acceptable carrier.

### Claim 61 (depends on 60)

The pharmaceutical composition of claim 60 wherein the average size of said microcapsules is about 1-20 microns.

### Claim 62 (depends on 60)

The pharmaceutical composition of claim 60 wherein the average size of said microcapsules is about 20-300 microns.

### Claim 63 (depends on 60)

The pharmaceutical composition of claim 60 wherein the average size of said microcapsules is greater than about 300 microns.

### Claim 64 (depends on 37)

The microcapsule of claim 37 wherein said bioactive substance is a saturated or nearly saturated solution of a non-aqueous drug in a hydrocarbon solvent and said membrane is hydrophilic.

### Claim 65 (depends on 37)

The microcapsule of claim 37 wherein said membrane is semi-permeable to said bioactive substance.
